Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1)

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 8, 2007, Pages 2179-2183

  Huang, Shenlin ^a   Li, Ronghua ^a   Connolly, Peter J ^a   Emanuel, Stuart ^a   Fuentes Pesquera, Angel ^a   Adams, Mary ^a   Gruninger, Robert H ^a   Seraj, Jabed ^a   Middleton, Steven A ^a   Davis, Jeremy M ^b   Moffat, David F C ^b  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b UCB PHARMA   (Belgium)

Author keywords

2 Amino 4 aryl 5 chloropyrimidine; CDK1; VEGFR 2

Indexed keywords

CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOLOGICAL ACTIVITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; FEMALE; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; CDC2 PROTEIN KINASE; CELL LINE, TUMOR; CELL PROLIFERATION; MOLECULAR STRUCTURE; PHARMACOKINETICS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

RATTUS;

EID: 33947721745     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.01.086     Document Type: Article

References (24)

1. Carmeliet P., and Jain R.K. Nature 407 (2000) 249
2. Folkman J. Nat. Med. 1 (1995) 27
3. Ferrara N., Gerber H.P., and LeCouter J. Nat. Med. 9 (2003) 669
4. Dvorak H.F. J. Clin. Oncol. 20 (2002) 4368
5. Strumberg D. Drugs Today 41 (2005) 773
6. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., and Rini B.I. J. Clin. Oncol. 24 (2006) 16
7. Connell R.D. Expert Opin. Ther. Patent 12 (2002) 1763
8. Boyer S.J. Curr. Top. Med. Chem. 2 (2002) 973
9. Traxler P. Expert. Opin. Ther. Targets 2 (2003) 215
10. Harper J.W., and Adams P.D. Chem. Rev. 101 (2001) 2511
11. Sielecki T.M., Boylan J.F., Benfiled P.A., and Trainor G.T. J. Med. Chem. 43 (2000) 1
12. Toogood P.I. Med. Res. Rev. 21 (2001) 487
13. Fischer P.M., and Gianella-Borradori A. Expert Opin. Investig. Drugs 12 (2003) 955
14. Sausville E.A. Curr. Med. Chem.-Anti-Cancer Agents 3 (2003) 47
15. Misra R.N., Xiao H., Kim K.S., Lu S., Han W., Barbosa S.A., Hunt J.T., Rawlins D.B., Shan W., Ahmed S.J., Qian L., Chen B., Zhao R., Bednarz M.S., Kellar K.A., Mulheron J.G., Batorsky R., Roongta U., Kamath A., Marathe P., Ranadive S.A., Sack J.S., Tokarski J.S., Pavletich N.P., Lee F.Y.F., Webster K.R., and Kimball S.D. J. Med. Chem. 47 (2004) 1719
16. Emanuel S., Gruninger R.H., Fuentes-Pesquera A., Connolly P.J., Seamon J.A., Hazel S., Tominovich R., Hollister B., Napier C., D'Andrea M.R., Reuman M., Bignan G., Tuman R., Johnson D., Moffatt D., Batchelor M., Foley A., O'Connell J., Allen R., Perry M., Jolliffe L., and Middleton S.A. Mol. Pharmacol. 66 (2004) 635
17. Davis, J. M.; Moffatt, D. F. C. U.S. Patent 6,600,037, 2003.
18. Imamoto T., Kusumoto T., Tawarayama Y., Sugiura Y., Mita T., Hatanaka Y., and Yokoyama M. J. Org. Chem. 49 (1984) 3904
19. Ishiyama T., Murata M., and Miyaura N. J. Org. Chem. 60 (1995) 7508
20. The boronates were made from the corresponding bromides using the procedure described in Ref. 14.
21. Upstate Cell Signaling Solutions, Serologicals Corporation, 706 Forest Street, Suite 1, Charlottesville, VA 22903, USA.
22. Zimmermann J., Caravatti G., Mett H., Meyer T., Mueller M., Lydon N.B., and Fabbro D. Archiv. der Pharmazie (Weinheim, Germany) 329 (1996) 371
23. Zimmermann J., Buchdunger E., Mett H., Meyer T., and Lydon N.B. Bioorg. Med. Chem. Lett. 7 (1997) 187
24. Huang S., Li R., Connolly P., Emanuel S., and Middleton S. Bioorg. Med. Chem. Lett. 16 (2006) 4818